amifostine anhydrous has been researched along with Fibrosarcoma in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The influence of tumor size on the ability of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) or misonidazole (MISO) to alter cyclophosphamide (CY) antitumor activity was investigated, using a chemically induced fibrosarcoma (FSA) and a spontaneous fibrosarcoma (NFSA) in C3Hf/Kam mice." | 3.66 | Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide. ( Hunter, N; Ito, H; Milas, L, 1983) |
| " A number of different paradigms of dosing route and schedule for the administration of the two agents have been investigated." | 1.29 | Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma. ( Chaney, SG; Holbrook, DJ; Thompson, DC; Wyrick, SD, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (84.62) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, MV | 1 |
| Rojas, A | 4 |
| Denekamp, J | 4 |
| Penhaligon, M | 1 |
| Milas, L | 6 |
| Hunter, N | 5 |
| Reid, BO | 1 |
| Thames, HD | 1 |
| Stewart, FA | 2 |
| Ito, H | 3 |
| Peters, LJ | 1 |
| McBride, WH | 1 |
| Thompson, DC | 1 |
| Wyrick, SD | 1 |
| Holbrook, DJ | 1 |
| Chaney, SG | 1 |
| Grdina, DJ | 1 |
| Kataoka, Y | 1 |
| Murley, JS | 1 |
| Teicher, BA | 1 |
| Crawford, JM | 1 |
| Holden, SA | 1 |
| Lin, Y | 1 |
| Cathcart, KN | 1 |
| Luchette, CA | 1 |
| Flatow, J | 1 |
13 other studies available for amifostine anhydrous and Fibrosarcoma
| Article | Year |
|---|---|
Tumor sensitization and protection: influence of stromal injury on estimates of dose modification.
Topics: Amifostine; Animals; Dose-Response Relationship, Radiation; Fibrosarcoma; Mice; Misonidazole; Neopla | 1984 |
Radioprotection of mouse skin vasculature and the RIF-1 fibrosarcoma by WR-2721.
Topics: Amifostine; Animals; Blood Vessels; Cell Survival; Dose-Response Relationship, Radiation; Female; Fi | 1984 |
Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Female; Fibrosarcoma; Gamma Rays; Jejunum; Lu | 1982 |
Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
Topics: Amifostine; Animals; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Interactio | 1983 |
Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Topics: Amifostine; Animals; Cyclophosphamide; Drug Interactions; Drug Therapy, Combination; Extremities; Fe | 1983 |
Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female | 1983 |
Time dependence of interaction of misonidazole and WR-2721.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug I | 1983 |
Need for studies on factors that influence radioprotection of solid tumors by WR-2721.
Topics: Amifostine; Animals; Fibrosarcoma; Humans; Mice; Organothiophosphorus Compounds; Radiotherapy Dosage | 1984 |
Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721.
Topics: Amifostine; Animals; Carcinoma; Dose-Response Relationship, Radiation; Female; Fibrosarcoma; Male; M | 1984 |
Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
Topics: Amifostine; Animals; Cyclophosphamide; Drug Antagonism; Female; Fibrosarcoma; Male; Mice; Mice, Inbr | 1984 |
Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma.
Topics: Amifostine; Animals; Biotransformation; Fibrosarcoma; Kidney; Male; Organoplatinum Compounds; Rats; | 1995 |
Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
Topics: Amifostine; Animals; Anticarcinogenic Agents; Antimutagenic Agents; Antineoplastic Agents, Alkylatin | 1999 |
Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.
Topics: Amifostine; Animals; Carmustine; Cell Line; Cyclophosphamide; Drug Interactions; Fibrosarcoma; Gluta | 1988 |